Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

Tumor-Stroma Interactions

Zhivka Hristova, Cindy Körner, Angelika Wörner, Sara Burmester, Birgitta Michels, Efstathios Vlachavas

The tumor microenvironment (TME) or tumor stroma comprises all cell types and extracellular matrix (ECM) that surrounds the tumor cells, jointly forming the tumor mass. The stromal compartment is comprised of immune cells from both, the innate and the adaptive systems, vascular cells, mesenchymal stem cells (MSC), cancer associated fibroblasts (CAF), and several other cell types. The TME affects tumor aggressiveness and the way tumor cells respond to therapies.

In several projects we are out to better understand how tumor and stromal cells impact on one another and cooperatively govern the phenotype of a particular cancer. Along these lines we have identified miR-1246 which is expressed in MSCs and regulates, via NF-KB signaling, the release of pro-inflammatory cytokines and chemokines (e.g., IL-6, CCL2, CCL5) [Bott et al. 2017]. We had previously identified miR-519a to confer resistance of luminal-like breast cancer to endocrine (tamoxifen) therapy [Ward et al. 2014]. More recently, we showed that the same miRNA also mediates apoptosis-resistance in breast cancer cells and their escape from recognition by natural killer (NK) cells [Breunig et al. 2017]. In collaboration with the group of Adit Ben-Baruch (Tel Aviv University) we showed that chemokine secretion is subtype-specific in breast cancer and that this is related to metastasis potential of tumors [Weitzenfeld et al., 2016, Liubimorski et al., 2019, Liubimorski et al., 2019, Dadiani et al., 2020].

Current research continues with MSCs and their interactions with tumor cells and extends towards the analysis of CAFs and immune cells in the context of breast cancer development and therapy response. To this end, we predominantly follow experimental in vitro and in vivo approaches [Berdiel et al., 2021, Maia et al., 2021].


Cytokine signaling: Adit Ben-Baruch (Tel Aviv)

Cell communication: Heidi Cerwenka (Mannheim)

Secretomics: Jeroen Krijgsveld (Heidelberg)

Clinics: Martina Vetter, Eva Kantelhardt (Halle/Saale), Andreas Schneeweiss (Heidelberg)

to top
powered by webEdition CMS